Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | CYBB | P04839 | 1/20 | 0.36 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.36 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.36 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 6/20 | 0.35 |
| ▸ | JAK2 | O60674 | 5/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26890664 | 0.86 | MEN1 (0.42) | MEN1KMT2AALDH1A1MAPTCTSK | |
| SCHEMBL25435841 | 0.83 | GPR119 (0.39) | MEN1KMT2AALDH1A1MAPTCTSK | |
| SCHEMBL26890665 | 0.81 | MEN1 (0.38) | MEN1KMT2ACYBBNOX5NOX4 | |
| SCHEMBL26686738 | 0.78 | MEN1 (0.43) | MEN1KMT2AMAPTCYBBNOX5 | |
| SCHEMBL25335687 | 0.78 | MEN1 (0.43) | MEN1KMT2AMAPTCYBBNOX5 | |
| SCHEMBL25337280 | 0.76 | NR1H2 (0.42) | MEN1KMT2AALDH1A1MAPTCYBB | |
| SCHEMBL26687047 | 0.76 | ADORA1 (0.42) | MEN1KMT2AALDH1A1MAPTCYBB | |
| SCHEMBL24535149 | 0.76 | MEN1 (0.40) | MEN1KMT2AMAPTCYBBNOX5 | |
| SCHEMBL25334805 | 0.76 | MEN1 (0.40) | MEN1KMT2AMAPTCYBBNOX5 | |
| SCHEMBL30793901 | 0.75 | MEN1 (0.38) | MEN1KMT2AMAPTCYBBNOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624052-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2025034919-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2025034883-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-4475956-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023154766-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | MEN1 667/4885KMT2A 2875/4885ALDH1A1 3974/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | MEN1 551/4885KMT2A 2868/4885ALDH1A1 3733/4885 |
| US-12624052-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | MEN1 1379/4885KMT2A 2918/4885ALDH1A1 3044/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | MEN1 551/4885KMT2A 2868/4885ALDH1A1 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.